Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
Date:10/21/2008

or the transaction.

A prospectus supplement relating to the new Convertible Senior Notes to be issued in the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company continues to have substantial amount of debt outstanding and the quarterly interest expense associated with the debt is significant; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch Logan

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Cell Therapeutics, Inc. Announces Reverse Stock Split
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
8. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
11. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... Tengion, Inc. (NASDAQ: TNGN ), a leader ... the Company,s Neo-Urinary Conduit™ (NUC) and Neo-Kidney Augment™ (NUC) ... North America Annual Conference being held December 11-14, in ... further supported by various cellular and molecular studies demonstrating ...
... Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation ... of a Phase 2 study of quizartinib (formerly AC220) ... 53rd Annual Meeting of the American Society of Hematology ... from two additional posters: one evaluating the pharmacodynamic effects ...
... 13, 2011 Tarsa Therapeutics today confirmed that it ... to the Food and Drug Administration (FDA) in the ... recombinant salmon calcitonin tablet for the treatment of postmenopausal ... that verified the results from Tarsa,s Phase III ORACAL ...
Cached Biology Technology:Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 2Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 3Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3
(Date:7/14/2014)... East Anglia have shown how the main psychoactive ingredient ... , Research published today reveals the existence of ... drug,s success in shrinking tumours. , It is ... equivalent with anti-cancer properties. , The research ... The team used samples of human breast cancer cells ...
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
Breaking Biology News(10 mins):UEA research reveals how cannabis compound could slow tumour growth 2Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... ON Physical activity is being increasingly recognized as ... Mammen,s review published in the October issue of the ... the connection one step further, finding that moderate exercise ... term. This is the first longitudinal review to ...
... Oct. 28, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2013.  ... decrease of 15% compared to $5.3 million in the same quarter ... was $1.2 million, or $0.05 per diluted share, which compares to ...
... age of agriculture that began in the 1960s, potassium chloride ... widely used as a major fertilizer in the Corn Belt ... recognized for their fundamental importance to soil fertility. Three University ... approach to potassium management that has been in place for ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2013 Financial Results 2Aware, Inc. Reports Third Quarter 2013 Financial Results 3Aware, Inc. Reports Third Quarter 2013 Financial Results 4Aware, Inc. Reports Third Quarter 2013 Financial Results 5Study challenges soil testing for potassium and the fertilizer value of potassium chloride 2Study challenges soil testing for potassium and the fertilizer value of potassium chloride 3Study challenges soil testing for potassium and the fertilizer value of potassium chloride 4
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Phosphatase ( l-PPase) is ... with activity towards phosphorylated ... residues. It is the ... the ORF221 open reading ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... refrigerated cold traps offers a choice of ... solvents or high volatility solvents. Ideal to ... evaporators. Also used for maintaining vapor-free gas ... in electron microscopes. Can be used as ...
Biology Products: